HUTCHMED licenses HMPL-A830 to GSK; source cites both $1.295B and $1.185B totals
HUTCHMED will get $110 million upfront as GSK takes global rights outside Greater China to the KRAS-EGFR conjugate HMPL-A830, with milestone figures stated differently across the filing.
HUTCHMED announced on September 3, 2026 that its subsidiary HUTCHMED Limited signed an exclusive development and license agreement with a subsidiary of GSK plc for HMPL-A830, described as a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate, granting the GSK subsidiary worldwide rights excluding Mainland China, Hong Kong, Macau and Taiwan to develop and commercialize HMPL-A830.1 Clinical development will initially focus on colorectal, pancreatic and lung cancer indications.1
The filing states deal value two different ways. In its opening summary, HUTCHMED describes an agreement including a US$110 million upfront payment and potential development, regulatory and commercial milestone payments, for up to a total of US$1.295 billion, and royalties on net sales.1 Later, the License Terms section of the same document states HUTCHMED Limited will receive an upfront payment of US$110 million and may receive additional development, regulatory and commercial milestone payments of up to a total of US$1.185 billion.1 The filing does not explain the difference between the two totals.
The GSK subsidiary GlaxoSmithKline Intellectual Property (No. 4) Limited will also pay tiered royalties on its annual net sales.1 HUTCHMED Limited will retain full development and commercialization rights in Mainland China, Hong Kong, Macau and Taiwan.1
On the clinical timeline, HUTCHMED Limited will be responsible for the global phase I development program, which is expected to start in the second half of 2026, registered under clinicaltrials.gov identifier NCT07718581.1 The GSK subsidiary will handle all subsequent clinical development and commercialization activities outside of Mainland China, Hong Kong, Macau and Taiwan.1 GSK also holds a right of first negotiation on one earlier stage ATTC drug candidate.1 The upfront payment is payable at closing, which is subject to customary closing conditions, including completion of any antitrust regulatory reviews.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.